Mesenchymal and induced pluripotent stem cell–based therapeutics: a comparison
Applied Microbiology and Biotechnology · 2023
DOI: 10.1007/s00253-023-12583-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Applied Microbiology and Biotechnology, 2023. Verfasst von Misha A Teale und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Biochemical Engineering and Cell Cultivation Techniques, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, …. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZHAW Zurich University of Applied Sciences.
Abstract (Originalsprache)
Stem cell–based cell therapeutics and especially those based on human mesenchymal stem cells (hMSCs) and induced pluripotent stem cells (hiPSCs) are said to have enormous developmental potential in the coming years. Their applications range from the treatment of orthopedic disorders and cardiovascular diseases to autoimmune diseases and even cancer. However, while more than 27 hMSC-derived therapeutics are currently commercially available, hiPSC-based therapeutics have yet to complete the regulatory approval process. Based on a review of the current commercially available hMSC-derived therapeutic products and upcoming hiPSC-derived products in phase 2 and 3, this paper compares the cell therapy manufacturing process between these two cell types. Moreover, the similarities as well as differences are highlighted and the resulting impact on the production process discussed. Here, emphasis is placed on (i) hMSC and hiPSC characteristics, safety, and ethical aspects, (ii) their morphology and process requirements, as well as (iii) their 2- and 3-dimensional cultivations in dependence of the applied culture medium and process mode. In doing so, also downstream processing aspects are covered and the role of single-use technology is discussed. Key points • Mesenchymal and induced pluripotent stem cells exhibit distinct behaviors during cultivation • Single-use stirred bioreactor systems are preferred for the cultivation of both cell types • Future research should adapt and modify downstream processes to available single-use devices
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Biochemical Engineering and Cell Cultivation Techniques, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Grüentalstrasse 14, 8820, Wädenswil, Switzerland. misha.teale@zhaw.ch.
- Centre for Biochemical Engineering and Cell Cultivation Techniques, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Grüentalstrasse 14, 8820, Wädenswil, Switzerland.
- Mares Advanced Therapies, 48268, Greven, Germany.
- Institute of Biotechnology, Chair of Bioprocess Engineering, Technical University of Berlin, ACK24, Ackerstraße 76, 13355, Berlin, Germany.
ORCID-Profile: Samuel Schneider, Dieter Eibl, Christian van den Bos, Peter Neubauer, Regine Eibl
Förderung
- ZHAW Zurich University of Applied Sciences
Zitieren
APA
Teale, M. A., Schneider, S., Eibl, D., van den Bos, C., Neubauer, P., & Eibl, R. (2023). Mesenchymal and induced pluripotent stem cell–based therapeutics: a comparison. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-023-12583-4
Vancouver
Teale MA, Schneider S, Eibl D, van den Bos C, Neubauer P, Eibl R. Mesenchymal and induced pluripotent stem cell–based therapeutics: a comparison. Applied Microbiology and Biotechnology. 2023. doi:10.1007/s00253-023-12583-4
BibTeX
@article{Teale2023,
author = {Teale, Misha A and Schneider, Samuel and Eibl, Dieter and van den Bos, Christian and Neubauer, Peter and Eibl, Regine},
title = {Mesenchymal and induced pluripotent stem cell–based therapeutics: a comparison},
journal = {Applied Microbiology and Biotechnology},
year = {2023},
doi = {10.1007/s00253-023-12583-4}
}
EUVIMED